Clinical data | |
---|---|
Other names | 3,4-Methylenedioxy-N-methylcathinone; Methylenedioxymethcathinone; MDMC; β-Keto-MDMA; βk-MDMA; M1; TSND-201; TSND201 |
Routes of administration | Common: oral, insufflation Uncommon: IV or IM injection, rectal |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Onset of action | 0.5 hours[3] |
Elimination half-life | 5.8–6.9 hours[3] |
Duration of action | 2.5–3.0 hours[3] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13NO3 |
Molar mass | 207.229 g·mol−1 |
3D model (JSmol) | |
Solubility in water | 357 mg/mL (20 °C) |
| |
| |
(what is this?) (verify) |
Methylone, also known as 3,4-methylenedioxy-N-methylcathinone (MDMC), is an empathogen and stimulant psychoactive drug. It is a member of the amphetamine, cathinone and methylenedioxyphenethylamine classes.
Methylone is a slight modification of 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy). It was first synthesized by the chemists Peyton Jacob III and Alexander Shulgin in 1996 for potential use as an antidepressant.[4] Methylone has been sold for recreational use, taking advantage of the absence of legal prohibition of this compound in many countries.[citation needed]